{"id":3842,"date":"2025-12-10T11:11:22","date_gmt":"2025-12-10T03:11:22","guid":{"rendered":"https:\/\/www.syfe.com\/magazine\/?p=3842"},"modified":"2025-12-10T11:11:25","modified_gmt":"2025-12-10T03:11:25","slug":"healthcare-trends-that-shape-genomics-and-biotechnology-companies","status":"publish","type":"post","link":"https:\/\/www.syfe.com\/magazine\/healthcare-trends-that-shape-genomics-and-biotechnology-companies\/","title":{"rendered":"Healthcare Innovation Portfolio: Balancing Exposure and Capturing Upsides"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Thanks to the convergence of AI, biotechnology, and our deepening understanding of human biology, we are closer than ever to transforming global healthcare systems. However, investing in this sector requires a strategic approach; on average, only a small fraction of drugs tested on humans make it to market, making stock picking risky. <\/p>\n\n\n\n

Syfe\u2019s Healthcare Innovation portfolio mitigates this by balancing exposure across genomics, biotechnology, pharmaceuticals, healthcare services, and medical devices, ensuring investors capture the upside of breakthroughs without being overexposed to the volatility of single-company clinical trials.\u00a0<\/p>\n\n\n\n

Rather than crack your head over identifying the next Moderna or Amgen, a portfolio like Syfe Healthcare Innovation <\/a>provides convenience as well as diversified exposure to multiple innovations across healthcare verticals.\u00a0<\/p>\n\n\n\n

How we built the Healthcare Innovation portfolio\u00a0<\/strong><\/h2>\n\n\n\n

To build the Healthcare Innovation portfolio, our investment team screened potential exchange-traded funds (ETFs) based on our rigorous selection criteria, choosing six that provided broad exposure to healthcare investment opportunities. The team is also constantly monitoring new healthcare themes for possible inclusion. <\/p>\n\n\n\n

Read more about our portfolio construction methodology here<\/a>.<\/p>\n\n\n\n

Our selection methodology includes looking at liquidity and size. Our ETFs are managed by well-established fund managers such as BlackRock and State Street Global Advisors.<\/p>\n\n\n\n

Following our November 2025 portfolio re-optimization, the portfolio now holds the following:<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Genomics: IDNA<\/strong><\/h3>\n\n\n\n

Unlock the code of life:<\/strong> The era of simply sequencing DNA is over; we are now in the age of editing it to cure diseases at their source. The iShares Genomics Immunology and Healthcare ETF (IDNA) allows investors to target the companies pioneering CRISPR gene editing, precision oncology, and agricultural biology. Rather than focusing on temporary solutions, the companies in this fund, such as those developing targeted cancer therapies and treatments for complex autoimmune disorders, are working on functional cures that address the root causes of illness. Top holdings are Exelixis Inc, Revolution Medicines Inc, Gilead Sciences<\/p>\n\n\n\n

Biotechnology and Medical Tech: IBB and HEAL<\/strong><\/h3>\n\n\n\n

Capture the next wave of medical breakthroughs:<\/strong> The iShares Biotechnology ETF (IBB) and iShares Healthcare Innovation UCITS ETF (HEAL) provide a dual-pronged approach to the sector. IBB focuses on established and emerging biotech leaders in the US that are revolutionizing treatments for rare genetic diseases, such as Cystic Fibrosis and Sickle Cell Disease. Meanwhile, HEAL offers global exposure to the “digitization” of health, investing in firms driving medical robotics and telemedicine. Together, they cover the spectrum from molecular biology to the digital infrastructure that delivers modern care.<\/p>\n\n\n\n